TransMedics Q4 revenue $31.4M (+225% YoY); guides FY2023 $138-145M

TransMedics Group, Inc.

2022-FY EPS reported -$1.23 revenue$93,459,000

Total revenue $31.4M in Q4 2022, up 225% from $9.7M in Q4 2021; full-year revenue $93.5M (+209%).
Net loss narrowed to $6.7M in Q4 2022 from $12.7M; full-year net loss $36.2M vs $44.2M in 2021.
Gross margin 66% in Q4 vs 72% prior year; full-year gross margin flat at 70%.
Cash and equivalents $201.2M as of Dec 31, 2022; operating expenses rose to $27.5M in Q4.
FY2023 revenue guidance $138-145M (48-55% growth); appointed Nick Corcoran as SVP Supply Chain in Jan 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported Full year 2023 results: revenue $138 million to $145 million. Guidance initiated.

Period: Full year 2023
Revenue: $138 million to $145 million
Guidance: initiated
Result: guidance update

Exact text from the filing

TransMedics expects total revenue for full-year 2023 to be in the range of $138 million to $145 million, which represents 48% to 55% growth compared to the company’s prior year revenue.

View on SEC.gov

Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-003766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.